[Does transurethral resection cause metastatic dissemination of hormone treated prostatic cancer?].
The evolution of non-metastatic prostate cancer treated with hormonal therapy does not appear to be affected by the performance of a transurethral resection (TUR) as a measure to expedite the common urinary tract. Of 82 patients followed for an interval ranging from 6 months to 15 years, 3 of 45 patients (6.7%) undergoing RUT experienced metastatic dissemination, while the same happened in 2 of 37 (5.4%) patients who did not undergo RUT, p being NS. The group of patients requiring RUT, however, experienced higher local progression rates, 22.2% vs 5.4%, a situation not ascribable to the RUT procedure but to the fact that such surgery was selectively indicated in neoplasias with larger tumoral mass.
Morote Robles
J
J
Servicio de Urología, Hospital General Valle de Hebrón, Barcelona.
Reig Ruiz
C
C
Vila Barja
J
J
Lorente Garin
J A
JA
López Pacios
M A
MA
de Torres Mateos
J A
JA
Soler Roselló
A
A
D000230:Adenocarcinoma / Q000209:etiology / Q000556:secondary* / Q000601:surgery / Q000628:therapy; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011468:Prostatectomy / Q000009:adverse effects*; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000601:surgery / Q000628:therapy; D012189:Retrospective Studies
Produce la RTU diseminación metastásica en el cáncer de próstata tratado hormonalmente?